首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

2126499

蛋白質表現市場：策略性洞察與預測（2026-2031年）

Protein Expression Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年08月20日 | 出版商:

Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計蛋白質表現市場將以7.61%的複合年成長率成長，從2025年的37.68億美元成長到2031年的58.52億美元。

全球蛋白質表現市場正經歷穩定成長，這主要得益於生物製藥產品線的擴張、生物相似藥的開發以及對生物製藥生產投資的增加。蛋白質表現技術對於生產用於治療、研發和工業應用的重組蛋白至關重要。該市場涵蓋多種表現系統，例如原核生物、哺乳動物細胞、昆蟲細胞和酵母，每種系統都適用於不同的蛋白質類型和應用。生物製藥產品線的擴張、生物相似藥開發計畫、細胞和基因治療研究以及對大規模生物製程的投資，日益影響市場需求趨勢。世界衛生組織（WHO）持續將生物製藥定位為治療癌症、自體免疫疾病、糖尿病和其他慢性疾病的重要組成部分，同時，已開發市場和新興市場的生產活動都在不斷擴大，生物相似藥的普及率也在不斷提高。然而，市場價值創造在整個價值鏈中的分佈並不均衡。高利潤的商業機會集中在哺乳動物表達平台、專有載體、特殊試劑、合約表達服務和製程開發解決方案等領域。採購決策因客戶群而異。科研機構優先考慮速度、方案相容性和可重複性，而製藥和生物技術公司則更注重表達產量、產品品質、可擴展性、監管文件和製程一致性。

市場促進因素

生物製藥開發平臺的擴展

生物製藥在腫瘤、免疫、代謝性疾病和罕見疾病的治療中日益重要。生物製藥的FDA批准和正在進行的臨床開發項目，從藥物發現和臨床前試驗到製程開發和商業化生產的各個階段，都需要大量生產重組蛋白。這種需求不僅限於成品治療藥物，還包括生長因子、酵素、抗體和檢測試劑。領先的供應商正透過擴大生物生產能力和生產支援服務來滿足這一需求。

生物相似藥生產活動活性化

生物相似藥正成為蛋白質表現需求的重要來源。世界衛生組織（WHO）指出，生物相似藥在臨床上與原廠生物製藥療效相當，同時顯著降低了治療成本。隨著越來越多的生物製藥專利到期，生產商正在尋求能夠以穩定品質和產量重現高度複雜蛋白質結構的表達系統。這一趨勢推動了對哺乳動物細胞表達技術、分析和表徵工具、製程最佳化服務以及法規遵從支援能力的需求成長。

合約開發和製造 (CDMO) 服務的成長

許多生技公司擴大選擇將蛋白質生產外包，而不是投資建造專用生產基礎設施。外包可以降低資本投入，並使他們能夠利用細胞株開發、上游工程、下游純化和規模化生產等方面的專業知識。領先的生命科學公司不斷擴展其合約開發和生產 (CDMO) 能力，這反映了客戶對一體化外包模式的需求。

擴大重組蛋白在科學研究工作流程的應用

蛋白質表現在藥物標靶檢驗、結構生物學、檢測方法開發、蛋白質體學和功能基因體學等領域仍然至關重要。大學、政府實驗室、生技公司和製藥公司需要持續供應重組蛋白和表現試劑，以支持其藥物研發活動。科學研究用途的需求與治療性藥物生產的需求有所不同，前者更注重柔軟性、快速交付和廣泛的蛋白供應，而非大規模生產的經濟效益。

市場限制因素

治療性蛋白質的生產，尤其是那些需要精確折疊和轉譯後修飾，十分複雜，導致生產成本和研發週期增加。漫長的製程開發和驗證週期會延長採購週期並增加切換成本。先進表達平台（尤其是哺乳動物細胞培養設施）的高額資本投資和營運成本，對中小型生物技術公司構成限制。技術變異性和產量最佳化方面的挑戰影響生產的經濟效益。研發產品的價格壓力正在擠壓某些產品類型的利潤空間。

The global protein expression market is experiencing steady growth, driven by the expansion of biologic drug pipelines, biosimilar development, and increasing investment in biopharmaceutical manufacturing. Protein expression technologies are essential for producing recombinant proteins used in therapeutics, research, and industrial applications. The market encompasses various expression systems, including prokaryotic, mammalian cell, insect cell, and yeast platforms, each suited to different protein types and applications. Demand conditions are increasingly shaped by the expansion of biologic drug pipelines, biosimilar development programs, cell and gene therapy research, and large-scale bioprocessing investments. The World Health Organization continues to identify biologics as an essential component of treatment for cancer, autoimmune disorders, diabetes, and other chronic diseases, while broader biosimilar adoption is expanding manufacturing activity across both developed and emerging markets. Value creation within the market is distributed unevenly across the value chain. High-margin opportunities are concentrated in mammalian expression platforms, proprietary vectors, specialized reagents, contract expression services, and process-development solutions. Purchasing decisions vary substantially across customer groups. Research laboratories prioritize speed, protocol compatibility, and reproducibility, while pharmaceutical and biotechnology companies place greater emphasis on expression yield, product quality, scalability, regulatory documentation, and process consistency.

Market Drivers

Expansion of Biologic Drug Development Pipelines

Biologic medicines continue to gain importance across oncology, immunology, metabolic disease, and rare disease treatment. FDA biological approvals and ongoing clinical development programs require substantial recombinant protein production throughout discovery, preclinical testing, process development, and commercial manufacturing. This demand extends beyond finished therapeutics to include growth factors, enzymes, antibodies, and assay reagents. Large suppliers are responding by expanding bioproduction capabilities and manufacturing support services.

Rising Biosimilar Manufacturing Activity

Biosimilars are becoming an important source of protein expression demand. According to the World Health Organization, biosimilars provide clinically equivalent alternatives to originator biologics while reducing treatment costs substantially. As additional biologic patents expire, manufacturers require expression systems capable of reproducing highly complex protein structures with consistent quality and yield. This trend is expanding demand for mammalian cell expression technologies, analytical characterization tools, process optimization services, and regulatory support capabilities.

Growth of Contract Development and Manufacturing Services

Many biotechnology companies increasingly outsource protein production rather than invest in dedicated manufacturing infrastructure. Outsourcing reduces capital requirements and provides access to specialized expertise in cell-line development, upstream processing, downstream purification, and scale-up activities. Major life science companies continue expanding contract development and manufacturing capabilities, reflecting customer demand for integrated outsourcing models.

Increasing Use of Recombinant Proteins in Research Workflows

Protein expression remains essential for drug target validation, structural biology, assay development, proteomics, and functional genomics. Universities, government laboratories, biotechnology firms, and pharmaceutical companies require continuous supplies of recombinant proteins and expression reagents to support discovery activities. Research demand differs from therapeutic manufacturing demand because customers prioritize flexibility, rapid turnaround, and broad protein availability rather than large-scale production economics.

Market Restraints

Complexity of therapeutic protein production, particularly for proteins requiring precise folding and post-translational modifications, increases production costs and development timelines. Lengthy process-development and validation requirements extend procurement cycles and create switching costs. High capital and operating costs for advanced expression platforms, especially mammalian cell culture facilities, constrain smaller biotechnology companies. Technical variability and yield optimization challenges affect manufacturing economics. Pricing pressure in research-grade products creates margin pressure in certain product categories.

Technology and Segment Insights

By Expression System

Mammalian cell expression represents the most commercially important segment because it supports production of complex therapeutic proteins requiring human-like post-translational modifications. Recombinant antibodies, fusion proteins, cytokines, and numerous biologics depend on mammalian hosts to achieve functional activity and regulatory acceptance. Buyer requirements in this segment differ markedly from those in prokaryotic expression. Pharmaceutical manufacturers prioritize glycosylation consistency, scalability, product quality, regulatory documentation, and process robustness. Competition centers on cell-line development capabilities, productivity improvements, media optimization, and process scalability. Prokaryotic systems remain important for simpler proteins and research applications. Insect cell, yeast, and other systems serve specific niches.

By Application

Therapeutic applications represent the largest and fastest-growing segment, driven by biologics development and biosimilar manufacturing. Research applications provide a stable base of reagent and vector consumption. Industrial applications include enzyme production and other non-pharmaceutical uses.

By Product

Reagents constitute a significant product category, including culture media, supplements, and detection reagents. Competent cells and expression vectors are essential tools for protein production. Services, including contract expression and process development, are a growing segment. Instruments support expression workflows.

Competitive and Strategic Outlook

The competitive landscape features major life science and bioprocessing suppliers. Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Agilent Technologies, QIAGEN, Takara Bio, Inc., Promega Corporation, New England BioLabs, Inc., Oxford Expression Technologies, and Lucigen Corporation compete across different portions of the value chain. Competition is increasingly influenced by the ability to provide complete workflow solutions rather than standalone products. Customers seek suppliers capable of supporting discovery, development, scale-up, validation, and commercial manufacturing within a unified ecosystem. Strategic investment continues to focus on bioprocessing infrastructure, cell-line engineering, automation, analytical technologies, and service expansion. Barriers to entry are moderate to high in advanced therapeutic applications due to regulatory requirements, technical expertise, intellectual property, and customer qualification processes.
Strategic developments include increasing product launches for optimized expression kits, acquisitions to expand enzyme and protease portfolios, and introductions of engineered host cell lines with improved productivity. Companies are expanding bioprocess design facilities and manufacturing infrastructure to support pharmaceutical and biotechnology customers. Partnerships and collaborations are strengthening research and development capabilities.

Conclusion

The protein expression market is poised for steady growth, driven by biologics development, biosimilar expansion, and continued investment in biopharmaceutical manufacturing. The evolution toward integrated workflow solutions and specialized expression platforms is reshaping the competitive landscape. Companies that successfully support customers throughout the full protein development lifecycle, demonstrate process efficiency, and maintain regulatory expertise are expected to lead the market. Ongoing technological innovation and expanding biologics pipelines will further support adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PROTEIN EXPRESSION MARKET BY EXPRESSION SYSTEM

5.1. Introduction
5.2. Prokaryotic
5.3. Mammalian Cell
5.4. Insect Cell
5.5. Yeast
5.6. Others

6. PROTEIN EXPRESSION MARKET BY APPLICATION

6.1. Introduction
6.2. Therapeutic
6.3. Industrial
6.4. Research

7. PROTEIN EXPRESSION MARKET BY PRODUCT

7.1. Introduction
7.2. Reagents
7.3. Competent Cells
7.4. Expression Vectors
7.5. Services
7.6. Instruments

8. PROTEIN EXPRESSION MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others